A single-institution prospective study was conducted to evaluate hearing loss rate after intensity modulated radiotherapy with concomitant cisplatin-based chemotherapy (CRT) for locally advanced head and neck cancer and identify cochlear dosimetric parameters associated with hearing loss risk.
Hearing loss after cisplatin-based chemoradiotherapy for locally advanced head and neck cancer: a prospective single-institution study / Musio, Daniela; DE Vincentiis, Marco; D'Urso, Pasqualina; Musacchio, Angela; Maiuri, Veronica; Zaccaro, Lucy; Ralli, Massimo; Marchetti, Claudia; Turchetta, Rosaria; Tombolini, Vincenzo; DE Felice, Francesca. - In: ANTICANCER RESEARCH. - ISSN 1791-7530. - 42:6(2022), pp. 3003-3009. [10.21873/anticanres.15784]
Hearing loss after cisplatin-based chemoradiotherapy for locally advanced head and neck cancer: a prospective single-institution study
DE Vincentiis, MarcoSecondo
;D'Urso, Pasqualina;Musacchio, Angela;Maiuri, Veronica;Zaccaro, Lucy;Ralli, Massimo;Marchetti, Claudia;Turchetta, Rosaria;Tombolini, VincenzoPenultimo
;DE Felice, Francesca
Ultimo
2022
Abstract
A single-institution prospective study was conducted to evaluate hearing loss rate after intensity modulated radiotherapy with concomitant cisplatin-based chemotherapy (CRT) for locally advanced head and neck cancer and identify cochlear dosimetric parameters associated with hearing loss risk.| File | Dimensione | Formato | |
|---|---|---|---|
|
Musio_Hearing loss_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
3.17 MB
Formato
Adobe PDF
|
3.17 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
